- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Arcapta Neohaler, Onbrez Breezhaler
Synonyms :
indacaterol
Class :
Drugs for asthma and COPD & Bronchodilators (Beta2-agonists/ Adrenergic agonists)
Dosage Forms & Strengths
Capsule, Inhalation:
75 mcg/capsule
chronic obstructive pulmonary disease (COPD)
1 capsule (75 mcg) is inhaled once a day
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
QTc interval is increased both by lenvatinib and indacaterol
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may increase the toxic effect of beta2 agonists
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
It may enhance the metabolism when combined with dexamethasone
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
may decrease the bronchodilatory effect of beta blockers
may have an increased tachycardic effect when combined with beta2-agonists
atosiban: they may increase the toxic effect of Beta2-Agonists
theophylline derivatives: they may increase the toxic effect of Beta2-Agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
Frequency defined:
1%-10%
Chest pain (2%)
Anxiety (2%)
Headache
Voice disorder
Diarrhea
Pruritis
Skin rash
Muscle cramps
Tremor
Abdominal pain
Vomiting
Nausea
Fever
<1%:
Angina pectoris
Cardiac arrhythmia
Cough
Dermatitis
Fatigue
Variable blood pressure
Restlessness
Nervousness
Pregnancy consideration: No adverse effects were reported in animal studies with indacaterol.
Lactation: Excretion of indacaterol in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Indacaterol
Pronounced: in-da-ka-te-rol
Why do we use indacaterol?
Indacaterol is a bronchodilator. It is used to open airways in lung diseases such as asthma and COPD where spasms may cause breathing problems.